Comparison
Maridebart Cafraglutide vs. Petrelintide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
no data
no data
Molecular weight
no data
no data
Half-life
no data
no data
Sequence
no data
no data
Mechanism of action
Maridebart Cafraglutide
MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.
Petrelintide
As an amylin analogue, petrelintide acts through amylin receptors, promoting satiety and slowed gastric emptying — a satiety pathway independent of the GLP-1 axis.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
1
of which in humans
1
1
Effects recorded
2
2
Open conflicts
0
0
Documented adverse events
1
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Maridebart Cafraglutide and Petrelintide?
- Maridebart Cafraglutide is classified as "Metabolic", while Petrelintide is classified as "Metabolic". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Maridebart Cafraglutide or Petrelintide?
- The highest available evidence level is "Human RCT" for Maridebart Cafraglutide and "Human RCT" for Petrelintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Maridebart Cafraglutide and Petrelintide in Germany and the United States?
- Germany: Maridebart Cafraglutide — Unapproved, Petrelintide — Unapproved. United States: Maridebart Cafraglutide — Unapproved, Petrelintide — Unapproved. These are factual summaries with source and review date on the individual pages.